Successful doxorubicin therapy of primary macroglobulinemia resistant to alkylating agents.
Two patients with macroglobulinemia refractory to alkylating agent therapy did have an objective response to therapy with doxorubicin. For patients refractory to alkylating agents, doxorubicin is an alternative to other alkylating agents or procarbazine.
D000368:Aged; D000477:Alkylating Agents / Q000627:therapeutic use*; D004317:Doxorubicin / Q000627:therapeutic use*; D004351:Drug Resistance; D005260:Female; D006801:Humans; D008875:Middle Aged; D008258:Waldenstrom Macroglobulinemia / Q000188:drug therapy*
D000477:Alkylating Agents; D004317:Doxorubicin